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Abstract We have previously shown that Nef-gene 10 fusion 
protein induces marked growth arrest of human primary CD4+ T 
cells. Here, in vitro cytostatic and cytotoxic activities of human 
immunodeficiency virus type 1 (HIV-I) Nef against CD4+ T 
cells were extensively investigated. Growth of human CD4+ cells 
was inhibited significantly just by the addition of purified full- 
length Nef to cultures. When Nef was cross-linked by anti-Nef 
antibodies, it became very cytocidal for CD4+ T cells. A high 
percentage of sera from HIV-l-infected individuals contained 
soluble Nef. Thus, soluble Nef in vivo may play an important role 
in immunodysfunction of CD4+ T lymphocytes in HIV-1 
infection. 
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tion with nylon wool, and selective panning selection as described 
previously [16]. CD4+ T cells from lamina propria mononuclear cells 
(LPMCs) were a gift from Dr. M. Ito, Yamagata University School of 
Medicine. The T cells from PBMC and LPMC were cultured in Is- 
cov's modified Dulbecco's medium (IMDM) containing 25 U/ml of 
rlL-2 and 10% heat-inactivated human AB serum (Gibco). 
2.2. Antibodies (Abs) and sera 
Mouse monoclonal antibodies (mAbs), OKT-4 (anti-CD4) and 
OKT-8 (anti-CD8), were purchased from Ortho Diagnostic Inc. 
Anti-Nef mAb (E7), for Nef antigen capture assay, was purified as 
described previously [16]. Hyperimmune anti-Nef serum was prepared 
by immunizing a specific pathogen-free rabbit with the purified Nef 
recombinant protein expressed by the baculovirus system as described 
previously [19]. HIV-l-seropositive sera were collected at the Sanjay 
Gandi Post-Graduate Institute for Medical Science Hospital in India 
as described previously [20]. 
1. Introduction 
The human immunodeficiency virus type 1 (HIV-1) con- 
tains various accessory (nef vif, vpr and vpu) [1] and regula- 
tory (tat and rev) genes in addition to structural genes (gag, 
pol and env) which are common to all retroviruses [2-7]. One 
of the accessory genes designated nef is located at the 3' end 
of the viral genome, partially overlapping the 3' long terminal 
repeat (LTR) and conserved in virtually all strains of HIV-1, 
HIV-2, and simian immunodeficiency viruses (SIVs). Recent 
reports have demonstrated that Nef  up-regulates viral replica- 
tion both in tissue cultures [8] and in animal systems [9,10]. 
HIV-1 infection causes serious depletion of CD4+ T lym- 
phocytes, that is essential for the development of AIDS. The 
basis for this drastic loss of T cells has not been elucidated as 
yet. It is unlikely that the observed depletion of T cells is a 
direct result of HIV-1 infection, since the cell population in- 
fected with the virus is so small [11-14]. Recently, several 
reports have indicated that HIV-1 gene products, such as 
Net', Tat, and Env, can induce T cell death [15-18]. These 
findings endorse the contention that a certain signal of T 
cell death may be attributable to critical accumulation of 
HIV-1 proteins. 
In this study, we demonstrate that the soluble form of Nef  
protein inhibits the proliferation of CD4+ T cells and that its 
cross-linking induces cytotoxic effects upon CD4+ T cells. We 
also show that soluble Nef  was detected frequently in the sera 
from individuals infected with HIV-1. 
2. Materials and methods 
2.1. Cells' 
As CD4+ human T cell lines, Molt4 and Molt4 clone 8 were used. 
CD4+ and CD8+ T cells from peripheral blood mononuclear cells 
(PBMCs) were prepared by centrifugation on Ficoll-Hypaque, separa- 
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2.3. Construction of the plasmids 
The preparation of the cDNA encoding the entire Nef (Net) (en- 
coding nucleotides 8343 9192 of the HTLV-III genome) and N-term- 
inal truncated Nef (t-Nef) (encoding nucleotides 8473 9192)-contain- 
ing baculovectors has been described previously [19]. The Nef 
plasmids pGEM101 (Nefl01) (encoding nucleotides 8473-9192) and 
pGEM123 (Nef123) (encoding nucleotides 8773-9192) were prepared 
as described previously [19]. The plasmid pGEM638 (Nef638) was 
constructed by cutting pGEM101 at the EcoRV-PvulI sites (encoding 
nucleotides 8473-9192), end filling with the Klenow polymerase, and 
then re-ligation (Fig. 1). 
2.4. Extraction and purification of recombinant Nef protein 
Nef fusion proteins and gene 10 protein expressed in E. coli, and 
the truncated Nef protein expressed by the baculovirus ystem were 
purified as described previously [16]. After extraction with 7 M urea 
and dialysis against 20 mM Tris-HC1 (pH 7.5), soluble proteins were 
added to a QAE Zetaprep disk. The fraction containing the Nef 
protein was further separated on a Sephadex G-200 chromatograph. 
Finally, the eluted Nef protein was purified on an Am-Gel 10 column 
(Bio-Rad Lab., Richmond, CA) coupled to anti-Nef mAb. The entire 
Nef protein expressed by the baculovirus ystem was purified by the 
above procedures using buffer containing 0.1% Triton X. The Gag 
p55 protein expressed by the baculovirus ystem was extracted and 
purified as described previously [19]. The purity of each recombinant 
protein was determined by immunoblotting analysis and the purity of 
the isolated products was over 98%. 
2.5. Proliferation assay 
The level of [3H]thymidine (TdR) incorporation was assayed as 
described previously [16]. Ceils (1 × 10 ~) were cultured with IMDM 
containing 10% heat-inactivated FBS or human AB serum in 96-well 
microplates (Becton Dickinson) in the presence of purified recombi- 
nant protein at a final concentration f 500 ng/ml for 3 days. The cells 
were pulse-labeled with 1 I.tCi of [3H]TdR for 6 h before harvesting. 
The percentage inhibition of [3H]TdR uptake by the cells was calcu- 
lated as follows: percentage of inhibition = {l-(cpm of experimental 
group in the presence of recombinant protein/cpm of control group in 
the absence of recombinant protein)} × 100. The number of cpm of 
the control group in the absence of recombinant protein was 
35 000 + 1200. 
2.6. Flow cytometry 
Flow cytometric analysis was performed essentially as described 
previously [16]. Cells were incubated for 30 min on ice with FITC- 
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conjugated OKT-4 and PE-conjugated OKT-8. After incubation and 
washing, cells were subjected to flow cytometric analysis by EPICS- 
XL. 
2. 7. Cytotoxic assay 
Cells (1 × l0 n) were incubated for 1 h on ice with the purified Nef 
protein and control gene 10 protein in 20 rtl of IMDM supplemented 
with 10% heat-inactivated FBS or human AB serum. After washing 
with the above medium, cells were cultured at 37°C in 0.I ml of 
complete IMDM in 96-weU plates previously coated at 4°C overnight 
with purified rabbit anti-Nef IgG (25 btg/ml). Cells were collected at 
day 3 or every day, and before cell harvesting at the end of the 
culture, propidium iodide (PI) (final concentration 5.0 ktg/ml) was 
added to cultures. The uptake of the DNA intercalating dye into cells 
was analyzed by flow cytometry with a 590 long-pass glass filter. The 
percentage of specific cell death was calculated as follows: percentage 
of cell death= {experimental incorporation of PI (%)-spontaneous 
incorporation of PI (%)/100%-spontaneous incorporation of PI 
(%)} × 100, The average of the spontaneous PI uptake in control 
cultures was 5.1%. 
2.8. Soluble Nef antigen assay 
Soluble Nef antigen in sera was measured by sandwich-type capture 
EL1SA. Wells of the microplate (Titertek Flow Lab., Irvine, UK) 
were coated with 100 lal of 1.0 ~g/ml purified rabbit anti-Nef IgG 
overnight at 4°C. After incubation with blocking buffer (PBS contain- 
ing 0.05% Tween 20 and 5% low-fat milk) at 37°C for 1 h, sample 
sera, culture supernatants from Molt4 clone 8 and purified entire Nef 
recombinant protein (as a standard) at 2-fold dilutions (100 rtl) were 
added to wells in duplicate. The plates were incubated overnight at 
4°C and then washed three times. After washing, 100 ~tl of 0.5 I.tg/ml 
purified anti-Nef mAb E7 were added and the plates were incubated 
at 37°C for 1 h. After washing, the reactive Abs were detected with a 
100-fold dilution of biotin-labeled goat anti-mouse ~t (Zymed Inc., 
South San Francisco, CA) for 1 h at room temperature. Finally, the 
plates were washed and incubated with streptavidin-conjugated alka- 
line phosphatase (1:100; Zymed) for 1 h at room temperature. This 
enzyme reaction was started by adding 0.25 mM p-nitrophenol phos- 
phate. Absorbance was measured by ELISA reader at 405 nm and the 
concentration of soluble Nef protein in the samples was calculated by 
interpolation from the standard curve. 
3.  Resu l ts  
3.1. Effect of Nef on the growth of T cells 
We have previously shown that Nef-gene 10 fusion protein 
inhibits proliferation of CD4+ T lymphocytes from PBMC 
[16]. We extended this analysis using CD4+ T cells from 
PBMC and LPMC, and Molt4 T cell lines. After addition 
of the entire Nef  protein expressed by the baculovirus ystem 
(Fig. 1), growth of CD4+ cells of various origins was mon- 
itored (Fig. 2). The cell growth of CD4+ T cells from PBMC 
and LPMC at day 3 was inhibited in the presence of Nef  
protein but not Gag p55 control protein. Similar results 
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Fig. 1. Structures of various Nef proteins used in this study. The 
entire Nef (Nef) and N-terminal truncated Nef (t-Nef) were ex- 
pressed by the baculovirus system. The truncated Nef-gene 10 fusion 
proteins (Nefl01, Nef123 and Nef638) were expressed by E. coli. 
Each recombinant protein was purified as described in Section 2. 
Numbers at the top represent the amino acid residues of Nef. 
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Fig. 2. Surface phenotype of T cells and suppression of CD4+ T 
cell proliferation by Nef. (Left) Phenotype of T cells from PBMC, 
LPMC and T cell lines was analyzed by flow cytometry with FITC- 
OKT-4 (hatched bars) and PE-OKT-8 (dotted bars). Percentages of 
positive cells were determined. (Right) Cells (1 × 105) were cultured 
for 3 days in complete medium containing entire Nef p27 (black) or 
Gag p55 (white) expressed by the baculosystem at a final concentra- 
tion of 0.5 ~tg/ml. Before 6 h of the end of culture, cells were pulse 
labeled with [3H]TdR. Percentage inhibition of [3H]TdR uptake was 
calculated as described in Section 2. 
were obtained with Molt4 clone 8 cells. In contrast, CD8+ 
T cells from PBMC, and Molt4 cells, which do not bind to the 
carboxyl-terminal domain of Nef  [19], did not show a signifi- 
cant decrease in [aH]TdR uptake. The growth inhibition of 
cells in the presence of Nef  was dose-dependent and this effect 
was noted at a minimal concentration of 5 ng/ml of Nef  (data 
not shown). 
3.2. Cytotoxic effect of Nef on T cells 
It is well known that cross-linkage of CD3 receptor on the 
cell surface causes activation of T cells as well as induction of 
T cell death. Recently, it has been reported that Nef-CD8 
fusion protein expressed on the cell surface induces T cell 
death [15]. We, therefore, examined the cytotoxic activity of 
Nef  cross-linked by anti-Nef Abs (Fig. 3). Death of CD4+ T 
cells from PBMC, as measured by incorporation of PI, by 
entire Nef and t-Nef was clearly observed at final concentra- 
tions of 10 ng/ml to 1 ktg/ml at day 3 (Fig. 3A,B). Similar 
results were obtained in Molt4 clone 8 cells (Fig. 3C,D). 
Among various versions of Nef-gene 10 proteins (Fig. 1), 
Nef  101 and 123 fusion proteins were cytotoxic for CD4+ T 
cells from PBMC and Molt4 clone 8 cells, but Nef  638 protein 
were not at all (Fig. 3). The difference in cytotoxicity between 
t-Nef and Nefl01 could be attributable to the chimeric struc- 
ture of Nefl01 (gene 10 protein and Net'). Cytotoxic activity 
of entire Nef  protein was found in CD4+ T cells from LPMC, 
but not in Molt4 cells (data not shown). In addition, anti-Nef 
mAb E7, which recognizes Nef epitope located at amino acid 
residues 192-206 [19], blocked the cytotoxicity by Nef  (data 
not shown). 
3.3. Detection of soluble Nef antigen in sera 
The level of soluble Nef  in sera of HIV-l- infected indivi- 
duals was monitored by antigen capture ELISA (Fig. 4). As 
control, culture supernatants of HIV-l- infected Molt4 clone 8 
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cells were used. The culture supernatants contained 0.5-5 ng/ 
ml of soluble Nef antigen. 21 sera out of 32 of HIV-1 sero- 
positive sera contained Nef at a concentration f 5-10 ng/ml, 
but Nef was not detected in 5 sera. These 5 sera contained 
high titers of anti-Nef antibodies (over 1:5000 by ELISA), 
whereas low levels of anti-Nef antibodies were found in the 
other sera [16]. In 28 control sera from healthy volunteers, 
soluble Nef antigen could not be found at all. These data 
indicate that effective Nef protein concentrations for T cell 
death could be reached in vivo. 
4. Discussion 
In this paper, we have described the cytostatic and cytolytic 
activities of soluble Nef antigen against CD4+ T cells. For 
cytotoxic activity of soluble Nef, it is essential that Nef binds 
to the CD4+ T cell surface and is cross-linked by anti-Nef 
Abs. We have previously found that the carboxyl-terminal 
region of Nef binds to CD4+ T cells derived from PBMC 
[19]. The carboxyl-terminal domain of Nef was also required 
for cytotoxic reaction against CD4+ T cells (Fig. 3). Although 
N-terminal truncated Nef (t-Nef) showed cytotoxic activity 
similar to that by entire Nef, Nef-gene 10 fusion proteins 
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Fig. 3. Cytotoxic effect of Nef. CD4+ T cells from PBMC (A,B) 
and Molt4 clone 8 cells (C and D) were incubated for 1 h on ice 
with entire Nef (©), t-Nef (v), Nefl01 ([]), Nef123 (zx), Nef 638 
(O), gene 10 (I) at the concentrations indicated. After incubation, 
cells were cultured for 3 days in the culture plates pre-coated with 
anti-Nef Ab (A,C). For kinetics, cells were incubated with 1 ktg/ml 
of recombinant proteins, and cultured as indicated in the plates pre- 
coated with anti-Nef Ab (B,D). Before harvesting cells, PI was 
added and cells were analyzed by flow cytometry. Percentage of spe- 
cific cell death was calculated as described in Section 2. (A) Control 
cultures in plates pre-coated with anti-Nef Ab. 
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Fig. 4. Detection of soluble Nef. Supernatants of Molt4 clone 8 
cells infected with HIV-1 (left), sera from healthy volunteers (center) 
and sera from individuals infected with HIV-I (right) were examined 
for the presence of soluble Nef by antigen capture ELISA as de- 
scribed in Section 2. Recombinant entire Nef added to a control 
serum was used for the standard curve. 
lacking the N-terminal portion of Nef (Nefl01 and Nef123) 
were less effective (Fig. 3). These results suggest hat for ef- 
fective cytotoxicity for CD4+ T cells, not only the C-terminus 
but also the N-terminus of Nef is needed. However, since 
none of the synthetic peptides tested induced the cytotoxic 
activity, it is likely that a certain conformational structure 
of the Nef is important for this reaction. 
We monitored the level of soluble Nef in sera of HIV-1- 
seropositive individuals (Fig. 4). A relatively high level of Nef, 
enough for cytotoxicity in vitro, was detected in many sera 
examined. As Nef was cytotoxic not only for PBMC-T but 
also for LPMC-T cells, it is conceivable that soluble Nef af- 
fects a process of specific loss of CD4+ T cells in HIV-1 
positive individuals. Whether Nef contributes much to selec- 
tive killing of T cells in HIV-1 infection needs to be deter- 
mined. 
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